Identification of FDA-approved drugs that increase mevalonate kinase in hyper IgD syndrome

被引:1
|
作者
Politiek, Frouwkje A. [1 ,2 ]
Turkenburg, Marjolein [1 ]
Koster, Janet [1 ]
Ofman, Rob [1 ]
Waterham, Hans R. [1 ,2 ,3 ,4 ]
机构
[1] Amsterdam Univ Med Ctr, Acad Med Ctr, Dept Lab Med, Lab Genet Metab Dis, Amsterdam, Netherlands
[2] Amsterdam Gastroenterol Endocrinol & Metab, Amsterdam, Netherlands
[3] Amsterdam Reprod & Dev, Amsterdam, Netherlands
[4] Amsterdam Univ Med Ctr, Acad Med Ctr, Lab Genet Metab Dis F0 222, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
关键词
cholesterol biosynthesis; clobetasol propionate; glucocorticoids; mevalonate kinase deficiency; systemic autoinflammatory diseases; HYPERIMMUNOGLOBULINEMIA-D; CHOLESTEROL; DEFICIENCY; MUTATIONS; PHENOTYPE; SERIES; BIOSYNTHESIS; GENOTYPE; SPECTRUM; CELLS;
D O I
10.1002/jimd.12698
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mevalonate kinase deficiency (MKD) is an autoinflammatory metabolic disorder caused by bi-allelic loss-of-function variants in the MVK gene, resulting in decreased activity of the encoded mevalonate kinase (MK). Clinical presentation ranges from the severe early-lethal mevalonic aciduria to the milder hyper-IgD syndrome (MKD-HIDS), and is in the majority of patients associated with recurrent inflammatory episodes with often unclear cause. Previous studies with MKD-HIDS patient cells indicated that increased temperature, as caused by fever during an inflammatory episode, lowers the residual MK activity, which causes a temporary shortage of non-sterol isoprenoids that promotes the further development of inflammation. Because an increase of the residual MK activity is expected to make MKD-HIDS patients less sensitive to developing inflammatory episodes, we established a cell-based screen that can be used to identify compounds and/or therapeutic targets that promote this increase. Using a reporter HeLa cell line that stably expresses the most common MKD-HIDS variant, MK-V377I, C-terminally tagged with bioluminescent NanoLuc luciferase (nLuc), we screened the Prestwick Chemical Library (R), which includes 1280 FDA-approved compounds. Multiple compounds increased MK-V377I-nLuc bioluminescence, including steroids (i.e., glucocorticoids, estrogens, and progestogens), statins and antineoplastic drugs. The glucocorticoids increased MK-V377I-nLuc bioluminescence through glucocorticoid receptor signaling. Subsequent studies in MKD-HIDS patient cells showed that the potent glucocorticoid clobetasol propionate increases gene transcription of MVK and other genes regulated by the transcription factor sterol regulatory element-binding protein 2 (SREBP-2). Our results suggest that increasing the flux through the isoprenoid biosynthesis pathway by targeting the glucocorticoid receptor or SREBP-2 could be a potential therapeutic strategy in MKD-HIDS.
引用
收藏
页码:302 / 316
页数:15
相关论文
共 50 条
  • [41] Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens
    Sisk, Jeanne M.
    Frieman, Matthew B.
    ACS INFECTIOUS DISEASES, 2015, 1 (09): : 401 - 402
  • [42] An analysis of FDA-approved drugs for inflammation and autoimmune diseases
    Kinch, Michael S.
    Merkel, Janie
    DRUG DISCOVERY TODAY, 2015, 20 (08) : 920 - 923
  • [43] RNA as an off-target for FDA-approved drugs
    Christopher R. Fullenkamp
    John S. Schneekloth
    Nature Chemistry, 2023, 15 : 1329 - 1331
  • [44] Hepatotoxicity of FDA-approved small molecule kinase inhibitors
    Jiang, Haochen
    Jin, Ying
    Yan, Hao
    Xu, Zhifei
    Yang, Bo
    He, Qiaojun
    Luo, Peihua
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (03) : 335 - 348
  • [45] FDA-approved small-molecule kinase inhibitors
    Wu, Peng
    Nielsen, Thomas E.
    Clausen, Mads H.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2015, 36 (07) : 422 - 439
  • [46] Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs
    Gu, Shuo
    Fu, Wing-Yu
    Fu, Amy K. Y.
    Tong, Estella Pui Sze
    Ip, Fanny C. F.
    Huang, Xuhui
    Ip, Nancy Y.
    SCIENTIFIC REPORTS, 2018, 8
  • [47] Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs
    Shuo Gu
    Wing-Yu Fu
    Amy K. Y. Fu
    Estella Pui Sze Tong
    Fanny C. F. Ip
    Xuhui Huang
    Nancy Y. Ip
    Scientific Reports, 8
  • [48] An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs
    Kinch, Michael S.
    Patridge, Eric
    DRUG DISCOVERY TODAY, 2014, 19 (10) : 1510 - 1513
  • [49] Deletion of a single mevalonate kinase (Mvk) allele yields a murine model of hyper-IgD syndrome
    Hager, E. J.
    Tse, H. M.
    Piganelli, J. D.
    Gupta, M.
    Baetscher, M.
    Tse, T. E.
    Pappu, A. S.
    Steiner, R. D.
    Hoffmann, G. F.
    Gibson, K. M.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2007, 30 (06) : 888 - 895
  • [50] Evaluating physiochemical properties of FDA-approved orally administered drugs
    Reese, Tanner C.
    Devineni, Anvita
    Smith, Tristan
    Lalami, Ismail
    Ahn, Jung-Mo
    Raj, Ganesh V.
    EXPERT OPINION ON DRUG DISCOVERY, 2024, 19 (02) : 225 - 238